1. Home
  2. LGCY vs LXEO Comparison

LGCY vs LXEO Comparison

Compare LGCY & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCY
  • LXEO
  • Stock Information
  • Founded
  • LGCY 2009
  • LXEO 2017
  • Country
  • LGCY United States
  • LXEO United States
  • Employees
  • LGCY N/A
  • LXEO N/A
  • Industry
  • LGCY
  • LXEO
  • Sector
  • LGCY
  • LXEO
  • Exchange
  • LGCY NYSE
  • LXEO Nasdaq
  • Market Cap
  • LGCY 89.1M
  • LXEO 93.9M
  • IPO Year
  • LGCY 2024
  • LXEO 2023
  • Fundamental
  • Price
  • LGCY $9.04
  • LXEO $2.72
  • Analyst Decision
  • LGCY Strong Buy
  • LXEO Strong Buy
  • Analyst Count
  • LGCY 2
  • LXEO 6
  • Target Price
  • LGCY $10.65
  • LXEO $18.50
  • AVG Volume (30 Days)
  • LGCY 63.4K
  • LXEO 984.8K
  • Earning Date
  • LGCY 05-15-2025
  • LXEO 05-12-2025
  • Dividend Yield
  • LGCY N/A
  • LXEO N/A
  • EPS Growth
  • LGCY 21.53
  • LXEO N/A
  • EPS
  • LGCY 0.62
  • LXEO N/A
  • Revenue
  • LGCY $58,970,210.00
  • LXEO N/A
  • Revenue This Year
  • LGCY $33.77
  • LXEO N/A
  • Revenue Next Year
  • LGCY $24.88
  • LXEO N/A
  • P/E Ratio
  • LGCY $14.53
  • LXEO N/A
  • Revenue Growth
  • LGCY 37.92
  • LXEO N/A
  • 52 Week Low
  • LGCY $3.60
  • LXEO $1.45
  • 52 Week High
  • LGCY $10.37
  • LXEO $19.50
  • Technical
  • Relative Strength Index (RSI)
  • LGCY N/A
  • LXEO 44.00
  • Support Level
  • LGCY N/A
  • LXEO $2.51
  • Resistance Level
  • LGCY N/A
  • LXEO $2.91
  • Average True Range (ATR)
  • LGCY 0.00
  • LXEO 0.42
  • MACD
  • LGCY 0.00
  • LXEO -0.04
  • Stochastic Oscillator
  • LGCY 0.00
  • LXEO 25.00

About LGCY LEGACY EDUCATION INC

Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Share on Social Networks: